U.S., July 9 -- ClinicalTrials.gov registry received information related to the study (NCT07054684) titled 'Study of BHV-1400 in IgA Nephropathy' on June 27.
Brief Summary: The purpose of this study is to determine if BHV-1400 is a safe and tolerable treatment in participantswith IgA Nephropathy (IgAN).
Study Start Date: July, 2025
Study Type: INTERVENTIONAL
Condition:
IgA Nephropathy
Intervention:
DRUG: BHV-1400
BHV-1400 is delivered subcutaneously (SC)
Recruitment Status: NOT_YET_RECRUITING
Sponsor: Biohaven Therapeutics Ltd.
Disclaimer: Curated by HT Syndication....